Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00102323
Status:
COMPLETED
Last Update Posted:
2022-11-07
First Post:
2005-01-27
Brief Title:
AMG 531 Treatment of Thrombocytopenic Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP Refractory to Splenectomy
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Randomized Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP Refractory to Splenectomy
Status:
COMPLETED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy of AMG 531 in the treatment of thrombocytopenia in subjects with ITP as measured by the platelet response This study will also evaluate changes in Patient Reported Outcomes and Health Resource Utilization due to treatment with AMG 531
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None